Search

Displaying results 5001 - 5010 of 5449 in total
  1. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10597
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  2. Drug

    Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10776
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  3. Drug

    Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10777
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  4. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10778
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  5. Drug

    Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10802
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  6. Drug

    Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen

    go.drugbank.com/drugs/DB11036
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  7. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    [A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.

  8. Drug

    Influenza A virus A/California/7/2009 (H1N1)-like hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14382
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  9. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14384
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  10. Drug

    Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14386
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it